2. Academic Validation
  3. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors

Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors

  • J Med Chem. 2010 Jun 10;53(11):4399-411. doi: 10.1021/jm1002793.
Norbert Höfgen 1,  Hans Stange,  Rudolf Schindler,  Hans-Joachim Lankau,  Christian Grunwald,  Barbara Langen,  Ute Egerland,  Peter Tremmel,  Menelas N Pangalos,  Karen L Marquis,  Thorsten Hage,  Boyd L Harrison,  Michael S Malamas,  Nicholas J Brandon,  Thomas Kronbach
Affiliations

Affiliation

  • 1 Biotie Therapies GmbH, Meissner Strasse 191, 01445 Radebeul, Germany. norbert.hoefgen@biotie.com
PMID: 20450197 DOI: 10.1021/jm1002793
Abstract

Novel imidazo[1,5-a]pyrido[3,2-e]pyrazines have been synthesized and characterized as both potent and selective phosphodiesterase 10A (PDE10A) inhibitors. For in vitro characterization, inhibition of PDE10A mediated cAMP hydrolysis was used and a QSAR model was established to analyze substitution effects. The outcome of this analysis was complemented by the crystal structure of PDE10A in complex with compound 49. Qualitatively new interactions between inhibitor and binding site were found, contrasting with previously published crystal structures of papaverine-like inhibitors. In accordance with the known antipsychotic potential of PDE10A inhibitors, MK-801 induced stereotypy and hyperactivity in rats were reversed by selected compounds. Thus, a promising compound class has been identified for the treatment of schizophrenia that could circumvent side effects connected with current therapies.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z